Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Share-based Compensation (2016 - 2026)

Akebia Therapeutics has reported Share-based Compensation over the past 10 years, most recently at $3.2 million for Q4 2025.

  • Quarterly Share-based Compensation rose 88.51% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.3 million through Dec 2025, up 45.12% year-over-year, with the annual reading at $11.3 million for FY2025, 45.12% up from the prior year.
  • Share-based Compensation was $3.2 million for Q4 2025 at Akebia Therapeutics, down from $3.2 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $6.9 million in Q2 2022 and troughed at $1.5 million in Q4 2023.
  • The 5-year median for Share-based Compensation is $3.1 million (2022), against an average of $3.4 million.
  • Year-over-year, Share-based Compensation tumbled 50.21% in 2023 and then soared 95.69% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $4.6 million in 2021, then plummeted by 34.4% to $3.0 million in 2022, then tumbled by 50.21% to $1.5 million in 2023, then increased by 12.09% to $1.7 million in 2024, then skyrocketed by 88.51% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Share-based Compensation are $3.2 million (Q4 2025), $3.2 million (Q3 2025), and $2.7 million (Q2 2025).